Evaluation of antibacterial activities for three commonly used antibiotics produced by different manufactures on female urinary tract infection Uropathogens in kalar city.

Authors

Mohammed H. Fatah, Department of Medical lab Technology, Kalar Technical College,Sulaimani Polytechnic University, SulaymaniyahFollow

Corresponding Author

Mohammed H. Fatah

Authors ORCID

0000-0001-6366-4216

Document Type

Research Article

Abstract

Health professional staff often claims information about trying to differentiate the used antibiotics based on the manufacturers that produce the drug, which may lead to a differentiation in the prescribing of the antibiotics by a physician. Numerous antibiotics produced by different manufactures, under different brands names are available in pharmacies for urinary tract infection (UTI) treatment; this study proceeds to find out and evaluates antibacterial activities of three most used antibiotics, produced by different antibiotic producers on uropathogens in Kalar city. Kirby–Bauer disk diffusion method is employed to assess antibacterial effectiveness of Amikacin (Ak), Levoflaxocilin (Lv) and Nitrofuratoin (Nr) against reference strains of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus saprophyticus and clinically isolated uropathogens (Escherichia coli, Pseudomonas aeruginosa, Staphylococcus saprophyticus, Proteus vulgaris, and Klebsiella pneumoniae). Inhibition zones (IZ) were determined in millimeter unit to show the activity of the antibiotics. It has been found that the activity of all brands on sensitive bacterial strains were in the preferred range and surpassed the threshold of (IZ) determined by Clinical Laboratories Standards Institute (CLSI) guide. The lack of significant differences among most tested brands for each antibiotic, support this idea

Keywords

Amikacin, Levofloxacin, Nitrofurantoin, manufactures, Uropathogens

How to Cite This Article

Fatah, Mohammed H. (2019) "Evaluation of antibacterial activities for three commonly used antibiotics produced by different manufactures on female urinary tract infection Uropathogens in kalar city.," Polytechnic Journal: Vol. 12: Iss. 1, Article 2.
DOI: https://doi.org/10.25156/ptj.v12n1y2022.pp8-15

References

Alshwaikh, R. M. A., Al-Sorchee, S. M. A., Ali, K. A., & al Beer, W. (2014). Antibacterial activity of parsley and celery aqueous extract on the isolated bacteria from children UTI in Erbil city. International J. Advance Res, 895–903.

Arabi, Y., Al-Shirawi, N., Memish, Z., & Anzueto, A. (2008). Ventilator-associated pneumonia in adults in developing countries: a systematic review. International Journal of Infectious Diseases, 12(5), 505–512.

Ball, P. (2003). Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review. Current Therapeutic Research, 64(9), 646–661.

Bauer, A. W., Kirby, W. M. M., Sherris, J. C., & Turck, M. (1966). Antibiotic Susceptibility Testing by a Standardized Single Disk Method.

Bonfiglio, G. (2001). Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy, 47(4), 239–242.

Brumfitt, W., & Hamilton-Miller, J. M. (1998). Efficacy and safety profile of long-term nitrofurantoin in urinary infections: 18 years’ experience. The Journal of Antimicrobial Chemotherapy, 42(3), 363–371.

Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019). Global contributors to antibiotic resistance. Journal of Global Infectious Diseases, 11(1), 36.

Cruciani, M., & Bassetti, D. (1994). The fluoroquinolones as treatment for infections caused by Gram-positive bacteria. Journal of Antimicrobial Chemotherapy, 33(3), 403–417.

Drago, L., de Vecchi, E., Mombelli, B., Nicola, L., Valli, M., & Gismondo, M. R. (2001). Activity of levofloxacin and ciprofloxacin against urinary pathogens. Journal of Antimicrobial Chemotherapy, 48(1), 37–45. Edlin, R. S., Shapiro, D. J., Hersh, A. L., & Copp, H. L. (2013).

Antibiotic resistance patterns of outpatient pediatric urinary tract infections. The Journal of Urology, 190(1), 222–227.

Fàbrega A, Madurga S, Giralt E, Vila J. Mechanism of action of and resistance to quinolones. Microb Biotechnol. 2009 Jan; 2(1):40-61. doi: 10.1111/j.1751-7915.2008.00063.x. Epub 2008 Oct 13. PMID: 21261881; PMCID: PMC3815421.

Ferrara, I., & Kong, Y. (2008). Can health insurance coverage explain the generic competition paradox? Economics Letters, 101(1), 48–52.

Humphries, R., Bobenchik, A. M., Hindler, J. A., & Schuetz, A. N. (2021). Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. Journal of Clinical Microbiology, 59(12), e00213-21.

Iliyasu, M. Y., Ezihe, M. I., & Bala, K. (2015). Antibiogram pattern of staphylococcus saprophyticus associated with asymptomatic bacteriuria among pregnant women attending antenatal clinics in bauchi metropolis. Nigerian Journal of Microbiology, 28, 2812–2820.

, L., & Isibor, J. O. (2017). Antibiotics Resistance and Plasmid Profiles of Staphylococcus aureus and Staphylococcus Saprophyticus Isolated From Patients in Ekpoma, Nigeria. Global Journal of Pathology and Microbiology, 5, 26–32.

Islam, M. B., Yusuf, M. A., Hassan, M., & Akter, S. (2019). Antimicrobial Sensitivity Pattern of the isolated Uropathogens at a Teaching Hospital. Journal of Science Foundation, 17(2), 42–45.

Johnson, J. R., & Russo, T. A. (2018). Acute Pyelonephritis in Adults (vol 378, pg 48, 2018). New England Journal of Medicine, 378(11), 1069.

Kashanian, J., Hakimian, P., Blute Jr, M., Wong, J., Khanna, H., Wise, G., & Shabsigh, R. (2008). Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU International, 102(11), 1634–1637.

Komp Lindgren, P., Klockars, O., Malmberg, C., & Cars, O. (2015). Pharmacodynamic studies of nitrofurantoin against common uropathogens. Journal of Antimicrobial Chemotherapy, 70(4), 1076–1082.

Kumar, A., Kumar, R., Gari, M., Keshri, U. S. P., Mahato, S. K., & Ranjeeta, K. (2017). Antimicrobial susceptibility pattern of urine culture isolates in a tertiary care hospital of Jharkhand, India. International Journal of Basic & Clinical Pharmacology, 6(7), 1733. https://doi.org/10.18203/2319- 2003.ijbcp20172740.

Kuti, J. L., Wang, Q., Chen, H., Li, H., Wang, H., & Nicolau, D. P. (2018). Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based.

breakpoints. Infection and Drug Resistance, 11, 783. Magaldi, S., Mata-Essayag, S., de Capriles, C. H., Pérez, C., Colella, M. T., Olaizola, C., & Ontiveros, Y. (2004). Well diffusion for antifungal susceptibility testing. International Journal of Infectious Diseases, 8(1), 39–45.

Maraki, S., Samonis, G., Karageorgopoulos, D. E., Mavros, M. N., Kofteridis, D., & Falagas, M. E. (2012). In vitro antimicrobial susceptibility to isepamicin of 6,296 Enterobacteriaceae clinical isolates collected at a tertiary care university hospital in Greece. Antimicrobial Agents and Chemotherapy, 56(6), 3067–3073.

Mascellino, M. T., Farinelli, S., Iegri, F., Iona, E., & de Simone, C. (1998). Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gramnegative isolates. Drugs under Experimental and Clinical Research, 24(3), 139–151.

McOsker, C. C., & Fitzpatrick, P. M. (1994). Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens. Journal of Antimicrobial Chemotherapy, 33(suppl_A), 23–30.

Mirzaei, A., Nasr Esfahani, B., Raz, A., Ghanadian, M., & Moghim, S. (2021).

From the Urinary Catheter to the Prevalence of Three Classes of Integrons, β-Lactamase Genes, and Differences in Antimicrobial Susceptibility of Proteus mirabilis and Clonal Relatedness with Rep-PCR. BioMed Research International, 2021. Novelli, A., & Rosi, E. (2017). Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections. Journal of Chemotherapy, 29(sup1), 10– 18.

Omri, A., & Ravaoarinoro, M. (1996). Comparison of the bactericidal action of amikacin, netilmicin and tobramycinin free and liposomal formulation against Pseudomonas aeruginosa. Chemotherapy, 42(3), 170–176.

Rizwan, M., Akhtar, M., Najmi, A. K., & Singh, K. (2018). Escherichia coli and Klebsiella pneumoniae sensitivity/resistance pattern towards antimicrobial agents in primary and simple urinary tract infection patients visiting university hospital of Jamia Hamdard New Delhi. Drug Research, 68(07), 415–420.

Sutherland, C. A., Verastegui, J. E., & Nicolau, D. P. (2016). In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates. Annals of Clinical Microbiology and Antimicrobials, 15(1), 1–7.

Tan, C., Graves, E., Lu, H., Chen, A., Li, S., Schwartz, K. L., & Daneman, N. (2017). A decade of outpatient antimicrobial use in older adults in Ontario: a descriptive study. Canadian Medical Association Open Access Journal, 5(4), E878–E885.

van de Sande-Bruinsma, N., Grundmann, H., Verloo, D., Tiemersma, E., Monen, J., Goossens, H., Ferech, M., & System, E. A. R. S. (2008). Antimicrobial drug use and resistance in Europe. Emerging Infectious Diseases, 14(11), 1722.

Publication Date

12-1-2019